Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

May 23, 2022

Conditions
Alzheimer DiseaseCognition Disorder
Interventions
DRUG

ACD856

Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.

DRUG

Placebo

Placebo oral solution

Trial Locations (1)

Unknown

Uppsala University Hospital, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AlzeCure Pharma

INDUSTRY

NCT05077501 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856 | Biotech Hunter | Biotech Hunter